A protein in tumor tissue may help predict meningioma growth
Original title: TOP2A Overexpression as a Prognostic Biomarker in High-Grade Meningioma: An Integrated Single-Cell and Bulk Transcriptomic Study.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
It was measured in tumor tissue from patients, but it is not a test or treatment yet.
The short version
Tumors with more of a protein called TOP2A tended to grow back sooner.
What was studied. Researchers studied tumor tissue from people with high grade meningioma. They checked a gene called TOP2A in 160 tumors and its protein in 154 tumors.
What they found. Tumors with more TOP2A were more often high grade or had come back. People with higher TOP2A levels saw their tumors grow again sooner. In 27 samples, extra copies of the TOP2A gene showed up in high grade tumors.
What this means, and what it doesn't
What it could mean: One day, doctors may use TOP2A to judge how a meningioma will act. That could help them plan how closely to watch it. TOP2A is not a treatment.
What it doesn't mean: This is not a new treatment, and it is not a cure. The work was done on stored tumor tissue, not in a trial. It is not a test your doctor can order for you today. The authors say it still needs to be checked in new patients first.
Source: PubMed, October 10, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.